CRL Net income
Net income at Charles River Laboratories fell to −$144M in fiscal 2025, the lowest in the 5 years reported, from $22M in 2024.
Net income attributable to the parent / common stockholders, as filed.
SOURCE: us-gaap:NetIncomeLoss · EDGAR CompanyFacts · CIK 1100682 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025−$144M
FY2024 $22M
HIGH$486M FY2022
LOW−$144M FY2025
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Net income | Change |
|---|---|---|
| FY2025 | −$144M | $-166M |
| FY2024 | $22M | $-452M |
| FY2023 | $475M | $-12M |
| FY2022 | $486M | +$95M |
| FY2021 | $391M | — |
More SAME DATA, OTHER VIEWS
Net income across coverage → · CRL company view →
Revenue · Operating cash flow · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.